2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2033

Mortality Prognostic Factors Of Patients With Systemic Autoimmune Diseases Admitted To An Intensive Care Unit
Abstract Number: 781

Mortality Rates, Readmissions and Revascularisation Following a First Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Compared With Controls
Abstract Number: 2917

Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Abstract Number: 2261

Motivations For Inadequate Persistence With Disease Modifying Anti-Rheumatic Drugs In Early Rheumatoid Arthritis: The Patient’s Perspective
Abstract Number: 2663

Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Abstract Number: 1136

MR T1ρ and T2 Of Meniscus After Acute Anterior Cruciate Ligament Injuries
Abstract Number: 288

MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI
Abstract Number: 2511

Multicenter Validation Of The Lupus Activity Scoring Tool (LAST) As Compared To The Selena Sledai (SS) Modification
Abstract Number: 510

Multicentric Analysis Of Inter and Intra Observer Reliabilities For Histopathological Abnormalities In Salivary Gland Biopsy In Primary Sjögren Syndrome
Abstract Number: 635

Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Abstract Number: 1459

Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Abstract Number: 1388

Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity
Abstract Number: 2561

Multiplex Cytokine Analysis Of Dermal Interstitial Blister Fluid In Systemic Sclerosis Defines Potential Pathogenic Pathways and Differentiates Clinical Subsets
Abstract Number: 88

Musculoskeletal Diseases Have The Worst Impact On Physical Health Compared With Other Diseases – Results Of The Dutch cross-Sectional Study
Abstract Number: 1043

Musculoskeletal Hospital Admissions Among Patients Treated For Rheumatoid Arthritis Between 1999 and 2010 Compared With The General Population In The Netherlands

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].